Serum Fetuin-A Associates with Type 2 Diabetes and Insulin Resistance in Chinese Adults by Song, Aiyun et al.
Serum Fetuin-A Associates with Type 2 Diabetes and
Insulin Resistance in Chinese Adults
Aiyun Song
1, Min Xu
1, Yufang Bi
1,Y uX u
1, Yun Huang
1, Mian Li
1, Tiange Wang
1, Yaohua Wu
1, Yu Liu
1,
Xiaoying Li
1,2, Yuhong Chen
1, Weiqing Wang
1, Guang Ning
1,2*
1Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrinology and Metabolism,
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to
Shanghai Jiao Tong University School of Medicine, Shanghai, China
Abstract
Background: Previous studies have demonstrated that fetuin-A is related to insulin resistance among subjects with normal
glucose tolerance but not patients with type 2 diabetes. There are limited data available concerning fetuin-A and insulin
resistance in Chinese. We aimed to study the association of feuin-A with insulin resistance among participants with or
without type 2 diabetes in a large sample size of adults aged 40 and older.
Methodology and Principal Findings: A community-based cross-sectional study was performed among 5,227 Chinese
adults. The average age of our study was 61.569.9 years. Serum fetuin-A concentrations were not significantly different
between male and female (296.9 vs. 292.9 mg/l, p=0.11). Compared with the lowest quartile, the highest quartile of serum
fetuin-A revealed a significant higher proportion of type 2 diabetic patients (34.8% vs. 27.3%, p,0.0001). In the multinomial
logit models, the risk of type 2 diabetes was associated with each one quartile increase of serum fetuin-A concentrations
when referenced not only to normal glucose tolerance (OR 1.24, 95% CI 1.07–1.43, p=0.004) but also to impaired glucose
regulation (OR 1.25, 95% CI 1.08–1.44, p=0.003, respectively), after adjustment for age, sex, community, current smoking,
and current drinking. The logistic regression analysis showed that fetuin-A were associated with elevated HOMA-IR and
fasting serum insulin both among the participants with or without type 2 diabetes in the full adjusted analysis. There was no
significant association between elevated serum fetuin-A concentrations and impaired glucose regulation (all p$0.12).
Conclusions and Significance: Higher fetuin-A concentrations were associated with type 2 diabetes and insulin resistance
in middle aged and elderly Chinese.
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Introduction
Serum fetuin-A (also called alpha-2 heremans schmid glyco-
protein, AHSG) is a multifunctional glycoprotein which is
exclusively secreted from hepatocytes in human [1]. For a long
time, fetuin-A has been considered to play a crucial role in the
protection from vascular calcification by solubilizing calcium and
phosphorus in serum [2–5]. It was also reported that fetuin-A
could inhibit insulin receptor tyrosine kinase activity through
blocking the autophosphorylation of tyrosine kinase and insulin
receptor substrate-1(IRS-1), and induced a lower-grade inflam-
mation [6,7], which resulted in insulin resistance [8–11].
Recently, epidemiological studies showed that serum fetuin-A
was associated with insulin resistance [12,13] and its co-
morbidities, such as metabolic syndrome [14,15] and type 2
diabetes [16,17].
Impaired glucose regulation (IGR), also termed as prediabetes
consisting of impaired fasting glucose and/or impaired glucose
tolerance (IFG and/or IGT) is definitely a risk factor for type 2
diabetes and cardiovascular disease [18,19]. The prediabetes is
abruptly increased in the world, as well as in China [20]. Insulin
resistance is a conspicuous characteristic of prediabetic states.
Thus, it is indispensable to evaluate the association of serum
fetuin-A with type 2 diabetes, as well as with prediabetes.
In the present study, we investigated the association of serum
fetuin-A with prediabetes, type 2 diabetes and insulin resistance in
a community-based Chinese population aged 40 or above.
Methods
Ethics statement
This study was approved by the Institutional Review Board of
the Ruijin Hospital, Shanghai Jiao Tong University School of
Medicine and was in accordance with the principle of the Helsinki
Declaration II. The written informed consent was obtained from
each participant.
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The participants were recruited from an ongoing glucose survey
in Youyi and Songnan communities, Baoshan, Shanghai in 2005
and 2008, respectively. The study population, design and protocols
of the study have been previously described [21,22]. In brief, we
first invited all registered permanent residents aged 40 or above by
poster advertisement and by mail to participate in a screening
examination. The screened subjects were allocated into 3
subgroups according to their fasting glucose concentrations of
7.0 mmol/l or above, 5.6 to 6.9 mmol/l and below 5.6 mmol/l.
We then selected randomly a case-control cohort from these 3
subgroups for further investigation, including a simplified 75-g oral
glucose tolerance test (OGTT), fasting and 2 hour blood and
urine sampling. We intended to compensate the potential low
participation rate of those with lower glucose levels by a defined
ratio of 1.0:1.2:1.4 in the above subgroups. The total 5847 subjects
were eventually allocated into normal glucose tolerance (NGT),
IGR and type 2 diabetes based on OGTT results. The participants
and non-participants were similar in characteristics, such as age
and sex distribution. The following subjects were excluded in the
final analysis, including those with more than five times of the
normal serum alanine aminotransferance (ALT), aspartate amino-
transferance (AST), or c-glutamyl transpeptadase (GGT) levels, or
with less than 30 ml/min/1.73 m
2 of the estimated glomerular
filtration rate (eGFR), or with self-reported fatty liver disease, or
missing serum fetuin-A concentrations, or with body mass index
(BMI) less than 18.5 kg/m
2 or great than 40 kg/m
2. Thus, a total
of 5227 subjects, including 2008 NGT, 1621 IGR and 1598 type 2
diabetic patients were included in the final analysis.
Clinical and biochemical measurements
Body height, body weight, and waist and hip circumferences
were measured by the experienced physicians. Blood pressure was
measured at the non-dominant arm in a seated position after a ten-
min rest using an automated electronic device (OMRON Model
HEM-752 FUZZY, Omron Company, Dalian, China). Three
measurements were taken in one minute apart and the average of
the three measurements was used in analysis.
All participants underwent OGTT after an overnight fast.
Fasting and 2 hour plasma glucose concentrations were measured
within one hour using the glucose oxidase method on an
autoanalyser (ADVIA-1650 Chemistry System, Bayer Corpora-
tion, Germany). Fasting serum insulin concentrations were
measured using an electrochemiluminescence assay (Roche-
Diagnostics, Switzerland). Fasting serum ALT, AST, GGT,
albumin, bilirubin, creatinine (SCR), triglycerides (TG), total
cholesterol (TC), high density lipoprotein cholesterol (HDL-C),
low density lipoprotein cholesterol (LDL-C) and high sensitivity C
reactive protein (hs-CRP) were measured using an autoanalyser
(ADVIA-1650 Chemistry System, Bayer Corporation, Germany).
Fasting serum fetuin-A concentrations were measured using a
human fetuin-A sandwich Enzyme Linked-Immuno-Sorbent assay
kit (MAB1184 R&D Company, CA, USA.). The inter and intra
assay coefficient of variation is 5.2% and 7.8%, respectively.
Definitions
Type 2 diabetes was diagnosed according to the 1999 World
Health Organization (WHO) criteria (fasting plasma glucose level
$7.0 mmol/l and/or 2-h OGTT plasma glucose level $11.1 mmol/
l, or taking anti-diabetic agents). IGR was defined as IFG (fasting
plasma glucose level $6.1 and ,7.0 mmol/l) and/or IGT (2 h
OGTT plasma glucose level $7.8 and ,11.1 mmol/l). Insulin
resistance index (homeostasis model assessment of insulin resistance,
HOMA-IR) was calculated using homeostasis model assessment
methods, as fasting insulin (IU/ml)6fasting glucose (mmol/L)/22.5.
The abbreviated Modification of Diet in Renal Disease (MDRD)
formula recalibrated for Chinese [23] was used to calculate the
eGFR expressed in mL/min per 1.73 m
2: eGFR=1866
[SCR60.011]21.1546[age]20.2036[0.742 if female]61.233,
where SCR is serum creatinine expressed as mmol/L and 1.233 is
the adjusting coefficient for Chinese. BMI was calculated as weight in
kilometers divided by height in meters squared. Waist-to-hip ratio
(WHR) was calculated as waist divided by hip circumference in the
same unit.
Statistical analysis
SAS version 8.1 (SAS Institute, Cary, NC) was used for
database management and statistical analysis. Measurements with
a skewed distribution, serum fetuin-A, TG, AST, ALT, GGT,
CRP and HOMA-IR were normalized by logarithmic transfor-
mation. Comparisons of means and proportions were performed
with the standard normal z-test and x
2 tests, respectively. To allow
for covariates and confounders, we performed analysis of
covariance and multiple linear and logistic regressions. Pearson
correlation analysis and multiple linear regression analysis were
performed to evaluate the association between serum fetuin-A and
the risk factors of type 2 diabetes. In order to eliminate the effect of
antidiabetic treatment on serum insulin and plasma glucose levels
as well as HOMA-IR, we performed the simple correlation and
multiple linear regression analysis by excluding the subjects who
were receiving oral antidiabetic treatment or insulin injection
(n=611). The subjects were also categorized into quartiles of
serum fetuin-A concentrations. Quartile 1 represents the lowest
and quartile 4 represents the highest one. We used the
multinomial logit analysis to evaluate the association of serum
fetuin-A with type 2 diabetes and IGR. The multivariate logistic
regression analysis was used to study the association of serum
fetuin-A with higher levels of HOMA-IR, fasting serum insulin. In
our study, subjects with equal to and/or more than the highest
quartile of HOMA-IR index, 2.18 in non-type 2 diabetes group
and 4.64 in type 2 diabetes group were defined as having insulin
resistance. Subjects with equal to and/or more than the highest
quartile of fasting serum insulin, 9.4 mIU/ml in non-type 2
diabetes group and 13.9 mIU/ml in type 2 diabetes were defined
as having elevated levels of fasting serum insulin.
Results
The distribution of serum Fetuin-A concentrations was
positively skewed with a median of 294.9 mg/l (inter-quartile
range 234.4–366.4 mg/l). Characteristics of study participants
among groups of NGT, Iso-IFG, Iso-IGT, IFG and IGT, and type
2 diabetes were shown in Table 1. The average age of our study,
including 2051 (39.2%) male and 3176 (60.8%) female, was
61.569.9 years. Serum fetuin-A concentrations were not signif-
icantly different between male and female (296.9 vs. 292.9 mg/l,
p=0.11). Serum fetuin-A concentrations in type 2 diabetic
patients were significantly higher than those with NGT or IGR,
after adjustment for age, sex and community (p=0.0008).
However, serum fetuin-A concentrations were not significantly
different between the participants with NGT and those with IGR
and among all sub-groups with IGR, including Iso-IFG, Iso-IGT,
IFG and IGT group (Iso-IFG vs Iso-IGT, 290.7 vs 290.5 mg/l,
P=0.46; Iso-IFG vs IFG and IGT, 290.7 vs 291.0 mg/l, p=0.95;
Iso-IGT vs IFG and IGT, 290.5 vs 291.0 mg/l, p=0.79) Among
1598 type 2 diabetic patients, 611 were given the treatment of oral
antidiabetic drugs or insulin injection. Among them, 575 patients
were given oral antidiabetic drugs and 84 were insulin injection
Fetuin-A, Diabetes and Insulin Resistance
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significantly different between patients with and without therapy
(301.8 vs 311.6 mg/l, p=0.42). The presences of type 2 diabetes
across fetuin-A quartile groups were 27.3%, 26.6%, 33.6%, and
34.8%, respectively. The presence of type 2 diabetes in the highest
fetuin-A quartile was higher than that in the lowest quartile
(p,0.0001). The presences of IGR across fetuin-A quartile groups
were 32.5%, 31.9%, 30.0%, 29.7%, respectively (p=0.07).
Serum feuin-A concentrations were positively correlated with
BMI, WHR, systolic and diastolic blood pressure, fasting serum
insulin concentrations, fasting and 2 hour plasma glucose,
HOMA-IR, serum TC, TG, and LDL-C (all p,0.007), and
negatively correlated with HDL-C(r=20.05, p=0.001) The
multivariate regression analysis showed that serum fetuin-A
concentrations were independently correlated with diastolic blood
pressure (b=0.002, p=0.006), fasting serum insulin concentra-
tions (b=0.03, p=0.0009), HOMA-IR (b=0.03, p=0.0002) and
serum TG (b=0.05, p,0.0001). We also investigated the
co-linearity between serum fetuin-A concentrations, BMI, WHR,
systolic and diastolic blood pressure, fasting serum insulin
concentrations, fasting and 2 hour plasma glucose, HOMA-IR,
serum TC, TG, HDL-C and LDL-C, and CRP. We found all the
variables were correlated between each other, but only the r value
between HOMA-IR and fasting serum insulin was great than 0.80
(r=0.97, p,0.0001).
The risk of IGR and type 2 diabetes in relation to quartiles of
serum fetuin-A was analyzed by using multinomial logit models.
Each one quartile increase of serum fetuin-A concentrations was
significantly associated with increased risk of type 2 diabetes when
referenced not only to NGT but also IGR (Model 2, OR 1.24,
95% CI 1.07–143, p=0.004; OR 1.25 95% CI 1.08–1.44,
p=0.003, respectively), after adjustment for age, sex, community,
current smoking, current drinking (Table 2). Referenced to IGR,
when further adjusted for BMI and WHR, or blood lipids, or
blood pressure, or CRP based on Model 2, the association
between fetuin-A and type 2 diabetes did not radically changed;
whereas referenced to NGT, the association between fetuin-A type
2 diabetes was remained after adjusted for blood pressure or CRP
and attenuated after adjustment for BMI or WHR (p=0.05 and
0.06, respectively). However, the associations disappeared when
further adjusted for HOMA-IR referenced not only to NGT but
also IGR (p=0.68 and 0.14, respectively). When adjusted the most
cofactors simultaneously, the association of fetuin-A and type 2
diabetes referenced to IGR still persisted (model 9, OR 1.21, 95%
CI 1.04–1.40, p=0.01). Even after excluding 611 subjects with
antidiabetic treatment or insulin injection, the odds ratio of the risk
of type 2 diabetes in relation to quartiles of serum fetuin-A
concentrations increased when adjusted for age, sex, community,
current smoking, current drinking, BMI, WHR, blood pressure,
TC, logTG, HDL-C, LDL-C and logCRP (OR 1.19, 95% CI
1.01–1.40, p=0.04). There was no significant association between
elevated serum fetuin-A concentrations and IGR (all p$0.12).
Among participants without type 2 diabetes, HOMA-IR and
fasting serum insulin concentrations increased across fetuin-A
Table 1. Characteristics of the study population.
Normal glucose
tolerance Impaired Glucose Regulation Type 2 diabetes p-value
Isolated IFG Isolated IGT IFG and IGT
Number 2008 515 602 504 1598
Demographics
Age (years) 59.369.6 60.469.3 62.4610.2 62.969.3 63.869.7 ,0.0001
Male, n (%) 711 (35.4) 218 (42.3) 229 (38.0) 188 (37.3) 705 (44.1) 0.0019
Current smoking, n (%) 420 (20.9) 89 (17.3) 110 (18.3) 67 (13.3) 314 (19.7) 0.9893
Current drinking, n (%) 281 (14.0) 76 (14.8) 100 (16.6) 66 (13.1) 245 (15.3) 0.7803
Measurements
Body mass index (kg/m
2) 24.563.1 24.963.1 25.763.3 25.863.1 26.363.6 ,0.0001
Waist/hip ratio 0.8860.06 0.8860.06 0.9160.06 0.9060.06 0.9260.06 ,0.0001
Systolic blood pressure (mmHg) 132621 136622 142622 143622 147622 ,0.0001
Diastolic blood pressure (mmHg) 77610 79610 80610 81610 81611 ,0.0001
Fasting plasma glucose (mmol/L) 4.960.4 5.960.3 4.960.4 6.060.4 7.662.4 ,0.0001
2 h OGTT plasma glucose (mmol/L) 6.061.1 6.461.0 8.960.9 9.161.0 16.065.1 ,0.0001
Fasting serum insulin (mIU/ml) 5.1 (4.9–5.2) 5.8 (5.5–6.2) 6.4 (6.1–6.8) 7.5 (7.0–8.0) 8.3 (8.0–8.6) ,0.0001
HOMA-IR 1.11 (1.07–1.14) 1.51 (1.41–1.62) 1.44 (1.35–1.53) 2.00 (1.87–2.14) 2.72 (2.62–2.82) ,0.0001
Total cholesterol (mmol/l) 4.9960.91 5.0060.88 5.1460.89 5.1060.99 5.1761.11 ,0.0001
Triglycerides (mmol/l) 1.22 (1.19–1.25) 1.36 (1.29–1.43) 1.48 (1.42–1.55) 1.65 (1.56–1.73) 1.76 (1.71–1.81) ,0.0001
HDL-cholesterol (mmol/l) 1.4260.34 1.4360.33 1.3660.33 1.3660.33 1.3160.32 ,0.0001
LDL-cholesterol (mmol/l) 2.4260.66 2.6860.74 2.5160.69 2.6660.75 2.5560.80 ,0.0001
Glomerular filtration rate ml/min/1.73 m
2 114.5642.3 119.0623.7 111.0624.1 116.4626.5 117.2631.4 ,0.0001
C-reactive protein (mg/l) 0.3 (0.3–0.4) 0.4 (0.4–0.5) 0.6 (0.5–0.7) 0.6 (0.5–0.7) 0.8 (0.7–0.9) ,0.0001
Fetuin-A (mg/l) 285.3 (231.9–359.1) 290.7 (226.9–372.9) 290.5 (234.5–359.2) 291.0 (230.0–359.9) 307.7 (243.5–376.2) 0.0008
Values are means 6 SD or median (inter-quartile range) or number (proportion).
p-values were for the ANOVA across the five groups after adjustments for age, sex and community, or chi-square analysis.
doi:10.1371/journal.pone.0019228.t001
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smoking, current drinking, BMI (both p for trend ,0.0001).
HOMA-IR in the fourth (1.41, 95% CI 1.34–1.47), the third
quartile (1.37, 95% CI 1.31–1.44) and in the second quartile (1.29,
95% CI 1.23–1.35) was significantly higher as compared with the
lowest quartile (1.20, 95% CI 1.14–1.25, p,0.0001, ,0.0001,
0.03, respectively, Fig. 1, panel A). Fasting serum insulin
concentrations in the highest quartile (6.04 mIU/ml, 95% CI
5.77–6.32), the third quartile (5.95 mIU/ml, 95% CI 5.68–6.23)
and the second quartile (5.56 mIU/ml, 95% CI 5.32–5.82) were
higher than those in the lowest quartile (5.18 mIU/ml, 95% CI
4.95–5.43, p,0.0001, ,0.0001, 0.03, respectively, Fig. 1, panel
C). The logistic regression analysis showed that the fetuin-A
concentrations were associated with the risk of increased HOMA-
IR and elevated fasting serum insulin after adjustment for the full
confounders (p for trend 0.0005, 0.009, respectively, Table 3).
Among participants with Type 2 diabetes, the similar results about
the association of fetuin-A with HOMA-IR and fasting serum
insulin concentrations were found (Table 3, Fig. 1, Panel B, D).
Discussion
To the best of our knowledge, this is the first report on serum
feruin-A and type 2 diabetes and insulin resistance in Chinese men
and women aged 40 or above. We found that serum fetuin-A
concentrations were significantly higher in type 2 diabetic patients
than subjects with NGR and IGR. Higher fetuin-A concentrations
were independently associated with risk of insulin resistance in not
only non-diabetic subjects, but also type 2 diabetic patients.
Epidemiology studies have shown that fetuin-A is associated
with incident type 2 diabetes in Americans aged more than 70-
years old [17] and in Germans aged 35 to 65 years old [16]. In
agreement with previous studies, we demonstrated that increased
fetuin-A concentrations were independently associated with the
presence of type 2 diabetes in middle aged and elderly Chinese.
The European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam study [16] found that the association
between circulating fetuin-A and type 2 diabetes was modified by
the existence of elevated glucose levels. They observed a positive
association among participants with elevated plasma glucose levels
within the nondiabetic range, whereas fetuin-A was not associated
with diabetes risk among participants with normal glucose levels.
In our study, we also found that in the participants with IGR,
higher fertuin-A concentrations tended to have more odds ratios
for prevalence of type 2 diabetes than that in those with NGT. As
we know, IGR was epidemic around the world, including in China
[20]. It was an important course and risk factor of development of
type 2 diabetes. Hence, we should pay more attention to serum
fetuin-A concentrations in those with IGR and those with other
risk factors for type 2 diabetes. However, we did not find the
association of elevated serum fetuin-A with the risk of IGR.
Moreover, fetuin-A concentrations were not significantly different
between the groups of NGT and IGR. So, we can assume that
fetuin-A is not most important during the course of development
from NGT to IGR. We found that in our study, serum fetuin-A
concentrations were not significantly different between Iso-IFG,
Iso-IGT, IFG and IGT group. Studies have demonstrated that
IFG and IGT have different pathophysiology [24]. Both IFG and
IGT had insulin resistance, but they differ in site of insulin
resistance. Individuals with IFG mainly had hepatic insulin
resistance and normal muscle insulin sensitivity, while individuals
with IGT predominantly were characterized by moderate to
severe muscle insulin resistance with normal to slightly reduced
hepatic insulin sensitivity. Fetuin-A resulted in insulin resistance
through binding insulin receptor tyrosine kinase in adepocytes and
skeletal muscle [9]. The elevated serum fetuin-A concentrations
might associate with adipose and skeletal muscle insulin resistance
other than hepatic insulin resistance. This was consistent to the
Table 2. The risk of impaired glucose regulation and type 2 diabetes in relation to quartiles of serum fetuin-A by using
multinomial logit models.
Impaired glucose regulation Type 2 diabetes
1 Type 2 diabetes
2
ORs (95% CI) p for trend ORs (95% CI) p for trend ORs (95% CI) p for trend
Model 1 0.97 (0.85–1.12) 0.72 1.26 (1.10–1.45) 0.001 1.30 (1.12–1.49) 0.0003
Model 2 0.99 (0.86–1.15) 0.93 1.24 (1.07–1.43) 0.004 1.25 (1.08–1.44) 0.003
Model 3 0.96 (0.83–1.11) 0.62 1.16 (1.00–1.34) 0.05 1.20 (1.04–1.40) 0.01
Model 4 0.96 (0.83–1.11) 0.57 1.15 (0.99–1.33) 0.06 1.20 (1.04–1.40) 0.01
Model 5 0.89 (0.77–1.03) 0.12 1.09 (0.94–1.26) 0.24 1.23 (1.06–1.42) 0.006
Model 6 0.98 (0.85–1.14) 0.82 1.23 (1.07–1.43) 0.005 1.25 (1.08–1.45) 0.002
Model 7 0.92 (0.79–1.07) 0.29 1.03 (0.89–1.20) 0.68 1.12 (0.96–1.30) 0.14
Model 8 0.96 (0.83–1.11) 0.56 1.20 (1.04–1.39) 0.01 1.25 (1.08–1.49) 0.002
Model 9 0.88 (0.75–1.02) 0.08 1.06 (0.91–1.23) 0.48 1.21 (1.04–1.40) 0.01
Data are odds ratios (ORs, 95% confidential interval).
Model 1, unadjusted;
Model 2, adjusted for age, sex, community, current smoking, and current drinking;
Model 3, based on model 2 further adjusted for BMI;
Model 4, based on model 2 further adjusted for WHR;
Model 5, based on model 2 further adjusted for blood lipids, including TC, logTG, HDL-C, LDL-C;
Model 6, based on model 2 further adjusted for blood pressure;
Model 7, based on model 2 further adjusted for logHOMA-IR;
Model 8, based on model 2 further adjusted for logCRP;
Model 9, based on model 2 further adjusted for BMI, WHR, blood pressure, TC, logTG, HDL-C, LDL-C, logCRP;
Type 2 diabetes
1, referenced to normal glucose tolerance; Type 2 diabetes
2, referenced to impaired glucose regulation;
Odds ratios were calculated with the use of multinomial logit models.
doi:10.1371/journal.pone.0019228.t002
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indicated as HOMA_IR, which was demonstrated highly
correlated with insulin resistance index derived from euglycemic
clamp in epidemiology [32].
In our study, we found that fetuin-A was positively correlated
with fasting serum insulin and HOMA-IR, the indicators of insulin
resistance in type 2 diabetes. It was well known, that insulin
resistance is the underlying mechanism of type 2 diabetes [25].
Previous studies demonstrated that feuin-A is a natural inhibitor of
the insulin receptor tyrosine kinase in vitro and in rodents [8–
11,26,27]. The rate of autophosphorylation of insulin receptor
tyrosine kinase and insulin receptor substrate-1 is decreased in rat
liver and skeletal muscle by injection of human recombinant
fetuin-A [9]. Fetuin-A knockout mice have improved insulin
sensitivity and are resistant to weight gain on a high-fat diet
[28,29]. In humans, high fetuin-A concentrations are associated
with insulin sensitivity determined during the euglycemic-hyper-
insulinemic clamp or HOMA-IR index in small sample size
nondiabetic subjects [12,13]. We added the evidence that in a
large sample size that serum fetuin-A was associated with insulin
resistance indicated as elevated HOMA-IR index and fasting
serum insulin levels. We found that the association between serum
fetuin-A and the risk of type 2 diabetes was no longer statistical
significant after adjustment for HOMA-IR. We could assume that
insulin resistance was an essential link between fetuin-A and type 2
diabetes. We also found that serum fetuin-A was associated with
insulin resistance in the diabetics. It was consistent with what was
found in small sample size men in Japanese [30]. However, in
Mori’s study [13], it was reported that insulin resistance may be
not exist in the diabetics, so the significant association between
fetuin-A and insulin resistance was not found. However, the
diabetics had the higher HOMA-IR and fasting serum insulin than
the non-diabetics had in our study. We thought that fetuin-A was
associated with insulin resistance unaffected by status of glucose
metabolism. It was also reported that fetuin-A can suppress the
production of adiponectin, an insulin-sensitizing adipokine [6].
The results suggested that there might be other pathways linked
between fetuin-A and insulin resistance. Further studies are
needed to explain the mechanisms between fetuin-A and insulin
resistance.
We found that fetuin-A concentrations were not significantly
associated with serum CRP concentrations in our study. Actually,
the association of fetuin-A and CRP was remained controversial
[4,6,16,17]. In humans, high serum fetuin-A levels were found to
be positively associated with metabolic syndrome and CRP,
suggesting that fetuin-A may be causally involved in the
pathophysiology of the condition of subclinical inflammation
[4,6]. However, the other study indicated that endogenous fetuin-
A can attenuate the inflammatory response [31]. They found a
previously unrecognized anti-inflammatory role of fetuin in
counter-regulating the innate immune response, and suggest that
it may be possible to use fetuin as an experimental anti-
inflammatory agent. However, the association of fetuin-A and
CRP and the role of fetuin-A in the pathogenesis of low-grade
inflammation needs to be studied further.
Limitations were unavoidable. Our study was a cross-sectional
design, it could not exactly serve as a causal infer. Further studies
are required not only to illustrate the mechanisms of change of
fetuin-A concentrations but also to explore the pathogenesis of the
association between increased of fetuin-A concentrations and the
risk of type 2 diabetes. The insulin resistance was evaluated by
HOMA-IR index or serum insulin levels, instead of the
Figure 1. Levels of HOMA-IR and fasting serum insulin across quartiles of serum fetuin-A concentrations among non-type 2
diabetes and type 2 diabetes. (A): Levels of HOMA-IR among non-type 2 diabetes group; (B): Levels of HOMA-IR among type 2 diabetes group;
(C): Levels of fasting serum insulin among non-type 2 diabetes; (D): Levels of fasting serum insulin among type 2 diabetes. Values are geometric
means (95% confidential intervals) of HOMA-IR and fasting serum insulin. The adjusted variables included age, sex, community, BMI, current smoking,
current drinking.
doi:10.1371/journal.pone.0019228.g001
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there is good correlation between estimates of insulin resistance
derived from HOMA and from the euglycemic clamp [32].
In conclusion, we found that higher fetuin-A concentrations
were independently associated with the risk of type 2 diabetes and
insulin resistance in middle aged and elderly Chinese. Insulin
resistance played an important role in the association between
fetuin-A and type 2 diabetes. Studies are needed to uncover the
mechanisms between elevated fetuin-A and insulin resistance and
type 2 diabetes.
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